Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...